Delcath reports Q3 2026 revenue of $35.1 million, up 71%, and raises guidance
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Total Revenue: $35.1 million in Q3 2026, up 71% from $20.6 million in Q3 2025. HEPZATO KIT Revenue: $32.7 million vs. $19.3 million prior year; volume up 19% sequentially and 72% year-over-year. CHEMOSAT Revenue: $2.4 million vs. $1.3…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong revenue growth and a raised outlook for a small-cap medical company may drive interest in the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 revenue was $35.1 million, versus $20.6 million in Q3 2025.
- 02HEPZATO KIT revenue was $32.7 million, with volume up 72% year-over-year.
- 03Net income was $7 million, compared with $0.8 million a year earlier.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets